3404
`
`723.
`
`724.
`
`725.
`
`726.
`
`727.
`
`728.
`
`729.
`
`730.
`
`731.
`
`732.
`
`733.
`
`?I$’:’,;M,
`
`Dolecek TA, Grandits G. Dietary polyunsaturated fatty
`acids and mortality in the Multiple Risk Factor
`lntervention Trial (MRFIT). World Rev Nutr Diet
`1991;66:205-16.
`
`Ascherio A, Rimm EB, Stampfer MJ, Giovannucci EL,
`Willett WC. Dietary intake of marine n-3 fatty acids,
`fish intake, and risk of coronary disease among men.
`NEngJMed1995;332:977-82.
`
`Morris MC, Manson JE, Rosner B, Buring JE, Willett
`WC, Hennekens CH. Fish consumption and cardiovas-
`cular disease in the Physicians' Health Study: a prospec-
`tive study. AmJEpidemiol 1995;142:166-75.
`
`Siscovick DS, Raghunathan TE, King I, Weinmann S,
`Wicklund KG, Albright J, Bovbjerg V, Arbogast P,
`Smith H, Kushi LH, Cobb LA, Copass MK, Psaty BM,
`Lemaitre R, Retzlaff B, Childs M, Knopp RH. Dietary
`intake and cell membrane levels of long-chain n-3
`polyunsaturated fatty acids and the risk of primary
`cardiac arrest. JAMA 1995;274:1363-7.
`Roche HM, Gibney MJ. Effects of long-chain n-3
`polyunsaturated fatty acids on fasting and postprandial
`triacylglycerol metabolism. Am J Clin Nutr
`2000;71(suppl):232S-7S.
`
`Harris WS. Fish oils and plasma lipid and lipoprotein
`metabolism in humans: a critical review. J Lipid Res
`1989;30:785-807.
`
`Harris WS. n-3 fatty acids and serum lipoproteins:
`human studies. Am J Clin Nutr 1997;65(suppl
`5):1645S-54S.
`
`Rissanen T, Voutilainen S, Nyyssonen K, Lakka TA,
`Salonen JR. Fish oil-derived fatty acids, docosahexaenoic
`acid and docosapentaenoic acid, and the risk of acute
`coronary events; the Kuopio lschaemic Heart Disease
`Risk Factor Study. Circulation 2000;102:2677-9.
`
`National Research Council. Toxicological effects of
`methylmercury. Washington, D.C.: National Academy
`Press, 1999.
`
`Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday
`RM, Sweetnam PM, Elwood PC, Deadman NM. Effects
`of changes in fat, fish and fibre intakes on death and
`myocardial reinfarction: Diet and Reinfarction Trial
`(DART). Lancet 1989;2:757-61.
`
`de Lorgeril M, Salen P, Martin J-L, Monjaud l, Delaye J,
`Mamelle N. Mediterranean diet, traditional risk factors,
`and the rate of cardiovascular complications after
`myocardial infarction: final report of the Lyon Diet
`Heart Study. Circulation 1999;99:779-85.
`
`734.
`
`735.
`
`736.
`
`737.
`
`738.
`
`739.
`
`740.
`
`741.
`
`742.
`
`743.
`
`744.
`
`Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V,
`Moshiri M. Randomized, double-blind, placebo-con-
`trolled trial of fish oil and mustard oil in patients with
`suspected acute myocardial infarction: the Indian
`Experiment of lnfarct survival-4. Cardiovasc Drugs
`Ther 1997; 11:485-91.
`
`GlSSl-Prevenzione lnvestigators. Dietary supplementa-
`tion with n-3 polyunsaturated fatty acids and vitamin E
`after myocardial infarction: results of the GlSSl-
`Prevenzione Trial. Lancet 1999;354:447-55.
`
`Sacks FM, Stone PH, Gibson CM, Silverman Dl, Rosner
`B, Pasternak RC, for the HARP Research Group.
`Controlled trial of fish oil for regression of human coro-
`nary atherosclerosis. JAm Coll Cardiol 1995;25:1492-8.
`von Schacky C, Angerer P, Kothny W, Theisen K,
`Mudra H. The effect of dietary (2-3 fatty acids on coro-
`nary atherosclerosis: a randomized, double-blind, place-
`bo-controlled trial. Ann Intern Med 1999; 130:554-62.
`
`Leaf A, Jorgensen MB, Jacobs AK, Cote G, Schoenfeld
`DA, Scheer J, Weiner BH, Slack JD, Kellet MA, Raizner
`AE, Weber PC, Mahrer PR, Rossouw JE. Do fish oils
`prevent restenosis after coronary angioplasty?
`Circulation 1994;90:2248-57.
`
`Nygard O, Nordrehaug JE, Refsum H, Ueland PM,
`Farstad M, Vollset SE. Plasma homocysteine levels
`and mortality in patients with coronary artery disease.
`NEnglJMed1997;337:230-6.
`
`Graham lM, Daly LE, Refsum HM, Robinson K,
`Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GHJ,
`lsraelsson B, Uiterwaal CS, Meleady R,
`Sheahan RG,
`McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H,
`Wautrecht JC, deValk HW, Sales Luis AC, Parrot-
`Roulaud FM, Tan KS, Higgins l, Garcon D, Medrano
`MJ, Candito M, Evans AE, Andria G. Plasma homocys-
`teine as a risk factor for vascular disease. The European
`Concerted Action Project. JAMA 1997;277:1775-81.
`Perry lJ, Refsum H, Morris RW, Ebrahim SB, Ueland
`PM, Shaper AG. Prospective study of serum total homo-
`cysteine concentration and risk of stroke in middle-aged
`British men. Lancet 1995;346:1395-8.
`
`Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde
`OH, Nordrehaug JE. Serum total homocysteine and
`coronary heart disease. lntJEpidemiol 1995;24:704-9.
`
`Stampfer MJ, Malinow MR, Willett WC, Newcomer
`LM, Upson B, Ullmann D, Tishler PV, Hennekens CH.
`A prospective study of plasma homocyst(e)ine and risk
`of myocardial infarction in US physicians. JAMA
`1992;268:877-81.
`
`Verhoef P, Kok FJ, Kruyssen DA, Schouten EG,
`Witteman JCM, Grobbee DE, Ueland PM, Refsum H.
`Plasma total homocysteine, B vitamins, and risk of
`coronary atherosclerosis. Arterioscler Thromb Vasc Biol
`1997;17:989-95.
`
`Downloaded from http://circ.ahaj0urnals.0rg/ by guest on November 13, 2014
`
`AM RNOO290177
`
`Hikma Pharmaceuticals
`
`IPR2022-00215
`
`Ex. 1008, p. 263 of 280
`
`

`

`745.
`
`746.
`
`747.
`
`748.
`
`749.
`
`750.
`
`751.
`
`752.
`
`753.
`
`754.
`
`Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH,
`for the MRFlT Research Group. Homocyst(e)ine and
`risk of cardiovascular disease in the Multiple Risk
`Factor lntervention Trial. Arterioscler Thromb Vasc Bio]
`1997;l7:1947-53.
`
`Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J,
`Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C.
`of serum homocysteine and lipoprotein(a)
`concentrations to atherosclerotic disease in a prospective
`:innish population based study. Atherosclerosis
`1994;l06:9-l9.
`
`ational Research Council. Dietary reference intakes for
`thiamin, riboflavin, niacin, vitamin B6, folate, vitamin
`312, pantothenic acid, biotin, and choline. Washington,
`D.C: National Academy Press, 2000. 567 pages.
`
`ational Research Council. Dietary reference intakes
`"or vitamin C, vitamin E, selenium, and carotenoids.
`Washington, D.C.: National Academy Press, 2000.
`509 pages.
`
`Blot WJ, Li J-Y, Taylor PR, Guo W, Dawsey S,
`Wang G-Q, Yang CS, Zheng SF, Gail M, Li G-Y, Yu Y,
`Liu B, Tangrea J, Sun Y, Liu F, Fraumeni JF Jr,
`Zhang Y-H, Li B. Nutrition intervention trials in
`Linxian, China: supplementation with specific
`vitamin/mineral combinations, cancer incidence,
`and disease-specific mortality in the general population.
`JNat] Cancer Inst l993;85:l483-92.
`
`Alpha-Tocopherol, Beta Carotene Cancer Prevention
`Study Group. The effect of vitamin E and beta carotene
`on the incidence of lung cancer and other cancers in
`male smokers. NEng]JMed l994;330:l029-35.
`
`Hennekens CH, Buring JE, Manson JE, Stampfer M,
`Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano
`JM, Ridker PM, Willett W, Peto R. Lack of effect of
`long-term supplementation with beta carotene on the
`incidence of malignant neoplasms and cardiovascular
`disease. NEng]JMed l996;334:ll45-9.
`
`Omenn GS, Goodman GE, Thornquist MD, Balmes J,
`Cullen MR, Glass A, Keogh JP, Meyskens FL Jr, Valanis
`B, Williams JH Jr, Barnhart S, Hammar S. Effects of a
`combination of beta carotene and vitamin A on lung
`cancer and cardiovascular disease. N Eng] J Med
`1996;334:l150-5.
`
`Stephens NG, Parsons A, Schofield PM, Kelly F,
`Cheeseman K, Mitchinson MJ. Randomised controlled
`trial of vitamin E in patients with coronary disease:
`Cambridge Heart Antioxidant Study (CHAOS).
`Lancet 1996;347:78l-6.
`
`Heart Outcomes Prevention Evaluation Study
`lnvestigators. Vitamin E supplementation and cardiovas-
`cular events in high-risk patients. N Eng] J Med
`2000;342:154-60.
`
`755.
`
`756.
`
`757.
`
`758.
`
`759.
`
`760.
`
`761.
`
`762.
`
`763.
`
`764.
`
`765.
`
`766.
`
`3405
`
`Criqui MH. Alcohol and coronary heart disease:
`consistent relationship and public health implications.
`C]1'n1'ca Chimica Acta l996;246:5l-7.
`
`If you drink alcoholic beverages
`Dufour MC.
`do so in moderation: what does this mean? J Nutr
`2001;l3l(suppl):552S-6lS.
`
`Criqui MH. Alcohol and hypertension: new insights from
`population studies. Eur Heart J l987;(suppl B):l9-26.
`Thun MJ, Peto R, Lopez AD, Monaco JH, Henley SJ,
`Heath CW, Doll R. Alcohol consumption and mortality
`among middle-aged and elderly U.S. adults. N Eng] J
`Med 1997;337:1705-14.
`
`Rimm EB, Williams P, Fosher K, Criqui M, Stampfer
`MJ. Moderate alcohol intake and lower risk of coronary
`heart disease: meta-analysis of effects on lipids and
`haemostatic factors. BMJ l999;3l9:l523-8.
`Rimm EB, Klatsky A, Grobbee D, Stampfer MJ. Review
`of moderate alcohol consumption and reduced risk
`of coronary heart disease: is the effect due to beer, wine
`or spirits? BMJ l996;3l2:73l-6.
`Fortson MR, Freedman SN, Webster PD III. Clinical
`assessment of hyperlipidemic pancreatitis. Am J
`Gastroentero] l995;90:2l34-9.
`
`Smith-Warner SA, Spiegelman D, Yaun S-S, van den
`Brandt PA, Folsom AR, Goldbohm A, Graham S,
`Holmberg L, Howe GR, Marshall JR, Miller AB,
`Potter JD, Speizer FE, Willett WC, Wolk A, Hunter DJ.
`Alcohol and breast cancer in women: a pooled analysis
`of cohort studies. JAMA l998;279:535-40.
`Criqui MH. Alcohol in the myocardial infarction
`patient. Lancet 1998;352:1873.
`
`Chobanian AV, Hill M. National Heart, Lung, and
`Blood Institute Workshop on Sodium and Blood
`Pressure: a critical review of current scientific evidence.
`Hypertension 2000;35:858-63.
`
`Appel LJ, Moore TJ, Obarzanek E, Vollmer WM,
`Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA,
`Windhauser MM, Lin P-H, Karanja N. A clinical trial
`of the effects of dietary patterns on blood pressure.
`NEng]JMed1997;336:11l7-24.
`
`Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray
`GA, Harsha D, Obarzanek E, Conlin PR, Miller ER lll,
`Simons-Morton DG, Karanja N, Lin P-H, for the
`DASH-Sodium Collaborative Research Group. Effects
`on blood pressure of reduced dietary sodium and the
`Dietary Approaches to Stop Hypertension (DASH) diet.
`NEng]JMed 200l;344:3-l0.
`
`767.
`
`Borchers AT, Keen CL, Stern JS, Gershwin ME.
`Inflammation and Native American medicine: the role
`of botanicals. Am J Clin Nutr 2000;72:339-47.
`
`Downloaded from http://circ.ahaj0urnals.0rg/ by guest on November 13, 2014
`
`AM RNOO290178
`
`Hikma Pharmaceuticals
`
`IPR2022-00215
`
`Ex. 1008, p. 264 of 280
`
`

`

`3406
`
`768.
`
`769.
`
`770.
`
`771.
`
`772.
`
`773.
`
`774.
`
`775.
`
`776.
`
`777.
`
`778.
`
`5;i%e>e:t%s;*me>i' ?I$’:’,;M,
`
`Jenkins DJ, Kendall CW, Axelsen M, Augustin LS,
`Vuksan V. Viscous and nonviscous fibres, nonabsorbable
`and low glycaemic index carbohydrates, blood lipids
`and coronary heart disease. Curr Opin Lipidol
`2000; 1 1:49-56.
`
`Hunninghake DB, Stein EA, Dujovne CA, Harris WS,
`Feldman EB, Miller VT, Tobert JA, Laskarzewski PM,
`Quiter E, Held J, Taylor AM, Hopper S, Leonard SB,
`Brewer BK. The efficacy of intensive dietary therapy
`alone or combined with lovastatin in outpatients with
`hypercholesterolemia. N Engl JMed 1993;328:1213-9.
`Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan
`JM, Cater NB. lncremental reduction of serum total
`cholesterol and low-density lipoprotein cholesterol with
`the addition of plant stanol ester-containing spread to
`statin therapy. Am J Cardiol 2000;86:46-52.
`Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA,
`Bouchard C, Buchner D, Ettinger W, Heath GW, King
`AC, Kriska A, Leon AS, Marcus BH, Morris J,
`Paffenbarger RS Jr, Patrick K, Pollock ML, Rippe JM,
`Sallis J, Wilmore JH. Physical activity and public health:
`a recommendation from the Centers for Disease Control
`and Prevention and the American College of Sports
`Medicine. JAMA 1995;273:402-7.
`Denke MA. Review of human studies evaluating individ-
`ual dietary responsiveness in patients with hypercholes-
`terolemia. Am J Clin Nutr 1995;62:471S-7S.
`Denke MA, Grundy SM.
`lndividual responses to a
`cholesterol-lowering diet in 50 men with moderate
`hypercholestrolemia. Arch Intern Med 1994; 154:317-25.
`
`lndividual responsiveness to a cholesterol-
`Denke MA.
`lowering diet in postmenopausal women with moderate
`hypercholesterolemia. Arch Intern Med 1994; 154:1977-
`82.
`
`Current Procedural Terminology: CPT 2001. Chicago,
`Illinois: American Medical Association, 2000. 300
`pages
`
`Connor SL, Gustafson JR, Sexton G, Becker N, Artaud-
`Wild S, Connor WE. The Diet Habit Survey: a new
`method of dietary assessment that relates to plasma
`cholesterol changes. JAm Diet Assoc 1992;92:41-7.
`Gans KM, Sundaram SG, McPhillips JB, Hixson ML,
`Linnan L, Carleton RA. Rate your plate: an eating
`pattern assessment and educational tool used at choles-
`terol screening and education programs. J Nutr Educ
`1993;25:29-36.
`
`Kris-Etherton P, Eissenstat B, Jaax S, Srinath U, Scott L,
`Rader J, Pearson T. Validation for MEDFICTS, a dietary
`assessment instrument for evaluating adherence to total
`and saturated fat recommendations of the National
`Cholesterol Education Program Step 1 and Step 2 diets.
`JAm Diet Assoc 2001; 101:81-6.
`
`779.
`
`780.
`
`781.
`
`782.
`
`783.
`
`784.
`
`785.
`
`786.
`
`787.
`
`788.
`
`789.
`
`790.
`
`Kristal AR, Abrams BF, Thornquist MD, Disogra L,
`Croyle RT, Shattuck AL, Henry HJ. Development and
`validation of a food use checklist for evaluation of
`community nutrition interventions. Am J Public Health
`1990;80:1318-22.
`
`Retzlaff BM, Dowdy AA, Walden CE, Bovbjerg VE,
`Knopp RH. The Northwest Lipid Research Clinic Fat
`lntake Sale: validation and utility. Am J Public Health
`1997;87:181-5.
`
`Peters JR, Quiter ES, Brekke ML, Admire J, Brekke MJ,
`Mullis RM, Hunninghake DB. The Eating Pattern
`Assessment Tool: a simple instrument for assessing
`dietary fat and cholesterol intake. J Am Diet Assoc
`1994;94:1008-13.
`
`Ammerman AS, Haines PS, DeVellis RF, Strogatz DS,
`Keyserling TC, Simpson RJ Jr, Siscovick DS. A brief
`dietary assessment to guide cholesterol reduction in
`low-income individuals: design and validation. J Am
`Diet Assoc 1991;91:1385-90.
`
`U.S. Department of Agriculture and U.S. Department
`of Health and Human Services. Nutritive value of foods.
`Home and Garden Bulletin no.72. Washington, D.C.:
`U.S. Department of Agriculture, 1981;399 pages.
`
`Lin B-H, Frazao E. Away-from-home foods increasingly
`important to quality of American diet. Agriculture
`Information Bulletin no. 749. Washington, D.C.: U.S.
`Department of Agriculture, 1999;22 pages.
`
`Pearson TA, Stone EJ, Grundy SM, McBride PE, Van
`Horn L, Tobin BW. Translation of nutritional sciences
`into medical education: the Nutrition Academic Award
`Program. AmJ Clin Nutr 2001;74:164-70.
`Van Horn L, Kavey R-E. Diet and cardiovascular disease
`prevention: what works? Ann Behav Med 1997; 19:197-
`2 12.
`
`Shepherd R, Stockley L. Nutrition knowledge, attitudes,
`and fat consumption. JAm Diet Assoc 1987;87:615-9.
`Prochaska JO, Velicer WF, Rossi JS, Goldstein MG,
`Marcus BH, Rakowski W, Fiore C, Harlow LL, Redding
`CA, Rosenbloom D, Rossi SR. Stages of change and
`decisional balance for 12 problem behaviors. Health
`Psychol 1994;13:39-46.
`
`Glanz K, Patterson RE, Kristal AR, DiClemente CC,
`Heimendinger J, Linnan L, McLerran DF. Stages of
`change in adopting healthy diets: fat, fiber, and
`correlates of nutrient intake. Health Educ Q
`1994;21:499-519.
`
`Baranowski T, Smith M, Baranowski J, Wang DT, Doyle
`C, Lin LS, Hearn MD, Resnicow K. Low validity of a
`seven-item fruit and vegetable food frequency question-
`naire among third-grade students. J Am Diet Assoc
`1997;97:66-8.
`
`Downloaded from http://circ.ahaj0urnals.0rg/ by guest on November 13, 2014
`
`AM RNOO290179
`
`Hikma Pharmaceuticals
`
`IPR2022-00215
`
`Ex. 1008, p. 265 of 280
`
`

`

`791.
`
`792.
`
`793.
`
`794.
`
`795.
`
`796.
`
`797.
`
`798.
`
`799.
`
`800.
`
`801.
`
`802.
`
`Bandura A. Self-efficacy: the exercise of control. New
`York: W.H. Freeman and Company, 1997. 500 pages.
`
`803.
`
`Perri MG. The maintenance of treatment effects in the
`long-term management of obesity. Clin Psychol Sci Prac
`1998;5:526-43.
`
`Ryder RE, Hayes TM, Mulligan lP, Kingswood JC,
`Williams S, Owens DR. How soon after myocardial
`infarction should plasma lipid values be assessed?
`BMJ1984;289:1651-3.
`
`O'Driscoll G, Green D, Taylor RR. Simvastatin, an
`HMG-Coenzyme A reductase inhibitor,
`improves
`endothelial function within 1 month. Circulation
`1997:9511 126-31.
`
`Stroes ES, Koomans HA, de Bruin TWA, Rabelink TJ.
`Vascular function in the forearm of hypercholestero-
`laemic patients off and on lipid-lowering medication.
`Lancet 1995;346:467-71.
`
`Tamai O, Matsuoka H, ltabe H, Wada Y, Kohno K,
`lmaizumi T. Single LDL apheresis improves endotheli-
`um-dependent vasodilation in hypercholesterolemic
`humans. Circulation 1997;95:76-82.
`
`Arntz H, Agrawal R, Wunderlich W, Schnitzer L, Stern
`R, Fischer F, Schultheiss H. Beneficial effects of pravas-
`tatin (icolestyramine/niacin) initiated immediately after
`a coronary event (the Randomized Lipid-Coronary
`Artery Disease [L-CAD] Study). Am J Cardiol
`2000;86:1293-8.
`
`Endo A. The discovery and development of HMG-CoA
`reductase inhibitors. JLipid Res 1992;33:1569-82.
`
`Tobert JA, Bell GD, Birtwell J, James I, Kukovetz WR,
`Pryor JS, Buntinx A, Holmes lB, Chao Y-S, Bolognese
`JA. Cholesterol-lowering effect of mevinolin, an
`inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A
`reductase, in healthy volunteers. J Clin Invest
`1982;69:913-9.
`
`Mabuchi H, Sakai T, Sakai Y, Yoshimura A, Watanabe
`A, Wakasugi T, Koizumi J, Takeda R. Reduction of
`serum cholesterol in heterozygeous patients with familial
`hypercholesterolemia: additive effects of compactin
`and cholestyramine. NEnglJMed 1983;308:609-13.
`
`Davignon J, Montigny M, Dufour R. HMG-CoA
`reductase inhibitors: a look back and a look ahead.
`CanJ Cardiol 1992;8:843-64.
`Mabuchi H, Haba T, Tatami R, Miyamoto S, Sakai Y,
`Wakasugi T, Watanabe A, Koizumi J, Takeda R. Effects
`of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme
`A reductase on serum lipoproteins and ubiquinone-10
`levels in patients with familial hypercholesterolemia.
`NEnglJMed1981;305:478-82.
`
`804.
`
`805.
`
`806.
`
`807.
`
`808.
`
`809.
`
`810.
`
`811.
`
`812.
`
`3407
`
`3ilheimer DW, Grundy SM, Brown MS, Goldstein JL.
`Mevinolin and colestipol stimulate receptor-mediated
`clearance of low density lipoprotein from plasma in
`"amilial hypercholesterolemia heterozygotes. Proc Natl
`Acad Sci USA 1983;80:4124-8.
`
`3royles FE, Walden CE, Hunninghake DB, Hill-Williams
`D, Knopp RH. Effect of fluvastatin on intermediate
`density lipoprotein (remnants) and other lipoprotein
`evels in hypercholesterolemia. Am J Cardiol
`1995;76:129A-35A.
`
`3akker-Arkema RG, Davidson MH, Goldstein RJ,
`Davignon J, lsaacsohn JW, Weiss SR, Keilson LM,
`3rown WV, Miller VT, Shurzinske LJ, Black DM.
`Efficacy and safety of new HMG-CoA reductase
`in patients with hypertriglyc-
`inhibitor, atorvastatin,
`eridemia. JAMA 1996;275:128-33.
`Arad Y, Ramakrishnan R, Ginsberg HN. Effects of
`lovastatin therapy on very-low-density lipoprotein
`triglyceride metabolism in subjects with combined
`hyperlipidemia: evidence for reduced assembly and
`secretion of triglyceride-rich lipoproteins. Metabolism
`1992;41:487-93.
`
`Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin
`therapy reduces low density lipoprotein apoB levels
`in subjects with combined hyperlipidemia by reducing
`the production of apoB-containing lipoproteins: implica-
`tions for the pathophysiology of apoB production.
`JLipid Res 1990;31:567-82.
`
`Twisk J, Gillian-Daniel DL, Tebon A, Wang L, Barrett
`PHR, Attie AD. The role of the LDL receptor in
`apolipoprotein B secreation. J Clin Invest
`2000;105:521-32.
`
`Postiglione A, Montefusco S, Pauciullo P, Mancini M,
`Piliego T. Effects of atorvastatin in patients with
`homozygous familial hypercholesterolemia [Letter]
`Atherosclerosis 1999; 147:423-4.
`
`lllingworth DR, Pilcher GJ, Marais
`Raal FJ, Pappu AS,
`AD, Firth JC, Kotze MJ, Heinonen TM, Black DM.
`Inhibition of cholesterol synthesis by atorvastatin in
`homozygous familial hypercholesterolaemia.
`Atherosclerosis 2000; 150142 1 -8.
`
`Marais AD, Naoumova RP, Firth JC, Penny C,
`Neuwirth CK, Thompson GR. Decreased production
`of low density lipoprotein by atorvastatin after apheresis
`in homozygous famililial hypercholesterolemia. J Lipid
`Res 1997;38:2071-8.
`
`Stein EA, Lane M, Laskarzewski P. Comparison of
`statins in hypertriglyceridemia. Am J Cardiol
`1998;81:66B-9B.
`
`Downloaded from http://circ.ahaj0urnals.0rg/ by guest on November 13, 2014
`
`AM RNOO29018O
`
`Hikma Pharmaceuticals
`
`IPR2022-00215
`
`Ex. 1008, p. 266 of 280
`
`

`

`3408
`
`813.
`
`814.
`
`815.
`
`816.
`
`817.
`
`818.
`
`819.
`
`820.
`
`821.
`
`822.
`
`5;i%e>e:t%s;*me>i' ?I$’:’,;M,
`
`Jones P, Kafonek S, Laurora l, Hunninghake D, for
`the CURVES Investigators. Comparative dose efficacy
`study of atorvastatin versus simvastatin, pravastatin,
`lovastatin and fluvastatin in patients with hypercholes-
`terolemia (The CURVES Study). Am ] Cardio]
`1998;81:582-7.
`
`Shepherd J. Fibrates and statins in the treatment of
`hyperlipidaemia: an appraisal of their efficacy and
`safety. Eur H e a r t ] 1995;16:5-13.
`
`Stein E. Cerivastatin in primary hyperlipidemia: a
`multicenter analysis of efficacy and safety. Am ] Cardio]
`1998;82:40J-6].
`
`Bradford RH, Shear CL, Chremos AN, Dujovne C,
`Downton M, Franklin FA, Gould AL, Hesney M,
`Higgins J, Hurley DP, Langendorfer A, Nash DT,
`Pool JL, Schnaper H. Expanded Clinical Evaluation
`of Lovastatin (EXCEL) study results. I. Efficacy in
`modifying plasma lipoproteins and adverse event profile
`in 8245 patients with moderate hypercholesterolemia.
`Arch Intern Med 1991;151:43-9.
`
`Hsu l, Spinler SA, Johnson NE. Comparative evaluation
`of the safety and efficacy of HMG-CoA reductase
`inhibitor monotherapy in the treatment of primary hyper-
`cholesterolemia. Ann Pharmacother 1995;29:743-59.
`
`Bradford RH, Shear CL, Chremos AN, Dujovne CA,
`Franklin FA, Grillo RB, Higgins J, Langendorfer A,
`Nash DT, Pool JL, Schnaper H. Expanded Clinical
`Evaluation of Lovastatin (EXCEL) study results:
`two-year efficacy and safety follow-up. Am ] Cardio]
`1994;74:667-73.
`
`Cressman MD, Hoogwerf BJ, Moodie DS, Olin JW,
`Weinstein CE. HMG-CoA reductase inhibitors: a new
`approach to the management of hypercholesterolemia.
`Cleve C]in]Med 1988;55:93-100.
`
`823.
`
`824.
`
`825.
`
`826.
`
`827.
`
`828.
`
`829.
`
`830.
`
`831.
`
`Hunninghake DB. Drug treatment of dyslipoproteine-
`mia. Endocrino] Metab Clin North Am 1990;19:345-60.
`
`832.
`
`lnsull W Jr, lsaacsohn J, Kwiterovich P, Ma P, Brazg R,
`Dujovne C, Shan M, Shugrue-Crowley E, Ripa S, Tota
`R, for the Cerivastatin Study Group. Efficacy and safety
`of cerivastatin 0.8 mg in patients with hypercholestero-
`laemia: the pivotal placebo-controlled clinical trial.
`Cerivastatin Study Group. ] I n t Med Res 2000;28:47-68.
`
`Davidson MH, Stein EA, Hunninghake DB, Ose L,
`Dujovne CA, lnsull W Jr, Bertolami M, Weiss SR,
`Kastelein JJP, Scott RS, Campodonico S, Escobar ID,
`Schrott HG, Bays H, Stepanavage ME, Wu M, Tate AC,
`Melino MR, Kush D, Mercuri M, Mitchel YB for the
`Worldwide Expanded Dose Simvastatin Study Group.
`Lipid-altering efficacy and safety of simvastatin 80
`mg/day: worldwide long-term experience in patients
`with hypercholesterolemia. Nutr Metab Cardiovasc Dis
`2000;10:253-62.
`
`Pierce LR, Wysowski DK, Gross TP. Myopathy and
`rhabdomyolysis associated with lovastatin-gemfibrozil
`combination therapy. ]AMA 1990;264:71-5.
`
`Goldman JA, Fishman AB, Lee JE, Johnson RJ. The role
`of cholesterol-lowering agents in drug-induced rhab-
`domyolysis and polymyositis [Letter]. Arthritis Rheum
`1989;32:358-9.
`
`Hanston PD, Horn JR. Drug interactions with HMG
`CoA reductase inhibitors. Drug Interactions Newsletter
`1998; 103-6.
`
`Wanner C, Kramer-Guth A, Galle J. Use of HMG-CoA
`reductase inhibitors after kidney and heart transplanta-
`tion: lipid-lowering and immunosuppressive effects.
`BioDrugs 1997;8:387-93.
`
`Gruer PJK, Vega JM, Mercuri MF, Dobrinska MR,
`Tobert JA. Concomitant use of cytochrome P450 3A4
`inhibitors and simvastatin. Am] Cardio] 1999;84:811-5.
`
`Davidson MH. Does differing metabolism by
`cytochrome P450 have clinical importance? Curr
`Atherosc]er Reports 2000; 1: 14-9.
`
`Hunninghake DB, Stein EA, Bremner WF, Greenland P,
`Demke DM, Oliphant TH. Dose-response study of
`colestipol tablets in patients with moderate hypercholes-
`terolemia. Am] Therapeut 1995;2:180-9.
`Superko HR, Greenland P, Manchester RA, Andreadis
`NA, Schectman G, West NH, Hunninghake D, Haskell
`WL, Probstfield JL. Effectiveness of low-dose colestipol
`therapy in patients with moderate hypercholesterolemia.
`Am] Cardio] 1992;70:135-40.
`
`Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J,
`lsaacsohn J, Toth P, Burke SK. Colesevelam
`Weiss S,
`hydrochloride (cholestagel): a new, potent bile acid
`sequestrant associated with a low incidence of gastroin-
`testinal side effects. Arch Intern Med 1999;159:1893-900.
`
`lnsull W Jr, Marquis NR, Tsianco MC. Comparison
`of the efficacy of Questran Light, a new formulation
`of cholestyramine powder, to regular Questran in main-
`taining lowered plasma cholesterol levels. Am ] Cardio]
`1991;67:501-5.
`
`833.
`
`834.
`
`Pravastatin Multicenter Study Group H. Comparative
`efficacy and safety of pravastatin and cholestyramine
`alone and combined in persons with hypercholes-
`terolemia. Arch Intern Med 1993; 153:1321-9.
`
`Heinonen TM, Schrott H, McKenney JM, Sniderman
`AD, Broyles FE, Zavoral JH, Kivel F, Black DM.
`Atorvastatin, a new HMG-CoA reductase inhibitor
`as monotherapy and combined with colestipol. ]
`Cardiovasc Pharamaco] Therapeut 1996; 1: 1 17-22.
`
`Downloaded from http://circ.ahaj0urnals.0rg/ by guest on November 13, 2014
`
`AMRNOO290181
`
`Hikma Pharmaceuticals
`
`IPR2022-00215
`
`Ex. 1008, p. 267 of 280
`
`

`

`835.
`
`836.
`
`837.
`
`838.
`
`839.
`
`840.
`
`841.
`
`842.
`
`843.
`
`844.
`
`845.
`
`846.
`
`Lovastatin Study Group. A multicenter comparison
`of lovastatin and cholestyramine therapy for severe
`primary hypercholesterolemia. JAMA 1988;260:359-66.
`Rudling MJ, Reihner E, Einarsson K, Ewerth S, Angelin
`B. Low density lipoprotein receptor-binding activity in
`human tissues: quantitative importance of hepatic recep-
`tors and evidence for regulation of their expression in
`vivo. Proc Natl Acad USA 1990;87:3469-73.
`
`Beil U, Crouse JR, Einarsson K, Grundy SM. Effects
`of interruption of the enterohepatic circulation of bile
`acids on the transport of very low density lipoprotein
`triglycerides. Metabolism 1982;31:438-44.
`
`Knopp RH. Drug treatment of lipid disorders.
`N EnglJMed1999;341:498-511.
`
`Knapp HH, Schrott H, Ma P, Knopp R, Chin B,
`Gaziano JM, Donovan JM, Burke SK, Davidson MH.
`Efficacy and safety of combination simvastatin and cole-
`sevelam in patients with primary hypercholesterolemia.
`Am JMed 2001;110:352-60.
`Davidson MH, Toth P, Weiss S, McKenney J,
`Hunninghake D, lsaacsohn J, Donovan JM, Burke SK.
`Low-dose combination therapy with colesevelam
`hydrochloride and lovastatin effectively decreases low-
`density lipoprotein cholesterol in patients with primary
`hypercholesterolemia. Clin Cardiol 2001;24:467-74.
`
`Denke MA, Grundy SM. Efficacy of low-dose choles-
`terol-lowering drug therapy in men with moderate
`hypercholesterolemia. Arch Intern Med 1995; 1551393-9.
`
`Gylling H, Miettinen TA. Lipid lowering during con-
`comitant cholesterol synthesis inhibition and cholesterol
`and bile acid malabsorption in coronary patients
`[Abstract]. Circulation 1999;100:l-825.
`
`Gylling H. Studies of plant stanol esters in different
`patient populations. European Heart Journal
`1999;1(suppl S):S109-S113.
`
`Crouse JR lll. Hypertriglyceridemia: a contraindication
`to the use of bile acid binding resins. Am J Med
`1987;83:243-8.
`
`Garg A, Grundy SM. Cholestyramine therapy for
`dyslipidemia in non-insulin-dependent diabetes mellitus:
`a short-term, double-blind, crossover trial. Ann Intern
`Med 1994; 121:416-22.
`
`Knopp RH, Ginsberg J, Albers JJ, Hoff C, Ogilvie JT,
`Warnick GR, Burrows E, Retzlaff B, Poole M.
`Contrasting effects of unmodified and time-release
`forms of niacin on lipoproteins in hyperlipidemic
`subjects: clues to mechanism of action of niacin.
`Metabolism 1985;34:642-50.
`
`847.
`
`848.
`
`849.
`
`850.
`
`851.
`
`852.
`
`853.
`
`854.
`
`855.
`
`856.
`
`857.
`
`858.
`
`859.
`
`3409
`
`Guyton JR, Goldberg AC, Kreisberg RA, Sprecker DL,
`Superko HR, O'Connor CM. Effectiveness of once-
`nightly dosing of extended-release niacin alone and in
`combination for hypercholesterolemia. Am J Cardiol
`1998;82:737-43.
`
`Drood JM, Zimetbaum PJ, Frishman WH. Nicotinic
`acid for the treatment of hyperlipoproteinemia.
`J Clin Pharmacol1991;31:641-50.
`Luria MH. Effects of low-dose niacin on high density
`lipoprotein cholesterol and total cholesterol/high density
`lipoprotein cholesterol ratio. Arch Intern Med
`1988; 14812493-5.
`
`Grundy SM, Mok HYl, Zech L, Berman M. Influence
`of nicotinic acid on metabolism of cholesterol and
`triglycerides in man. JLipid Res 1981;22:24-36.
`
`Langer T, Levi RI. The effect of nicotinic acid on the
`turnover of low density lipoproteins in type ll hyper-
`lipoproteinemia. ln: Gey KF, Carlson RA, eds.
`Metabolic effects of nicotinic acid and its derivatives.
`Bern, Germany: Hans Huber Publishers, 1971: 641-7.
`
`Superko HR, Krauss RM. Differential effects of
`nicotinic acid in subjects with different LDL subclass
`patterns. Atherosclerosis 1992;95:69-76.
`
`Knopp RH, Alagona P, Davidson M, Goldberg AC,
`Kafonek SD, Kashyap M, Sprecher D, Superko HR,
`Jenkins S, Marcovina S. Equivalent efficacy of a
`time-release form of niacin (Niaspan) given once-a-night
`versus plain niacin in the management of hyperlipi-
`demia. Metabolism 1998;47: 1097-104.
`
`McKenney JM, Proctor JD, Harris S, Chinchili VM.
`A comparison of the efficacy and toxic effects of
`sustained- vs immediate-release niacin in hypercholes-
`terolemic patients. JAMA 1994;271:672-7.
`lllingworth DR, Stein EA, Mitchel YB, Dujovne CA,
`Frost PH, Knopp RH, Tun P, Zupkis RV, Greguski RA.
`Comparative effects of lovastatin and niacin in primary
`hypercholesterolemia: a prospective trial. Arch Intern
`Med 1994;154:1586-95.
`
`Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC,
`Kreisberg RA, Brusco OA, Brody J. Efficacy and safety of
`an extended-release niacin (Niaspan): a long-term study.
`Am J Cardiol 1998;82:74U-81U;discussion 85U-86U.
`Guyton JR, Capuzzi DM. Treatment of hyperlipidemia
`with combined niacin-statin regimens. Am J Cardiol
`1998;82:82U-4U.
`
`Tato F, Vega GL, Grundy SM. Effects of crystalline
`nicotinic acid-induced hepatic dysfunction on serum
`low-density lipoprotein cholesterol and lecithin choles-
`teryl acyl transferase. Am J Cardiol 1998;81:805-7.
`Garg A, Grundy SM. Nicotinic acid as therapy for
`dyslipidemia in non-insulin-dependent diabetes mellitus.
`JAMA 1990;264:723-6.
`
`Downloaded from http://circ.ahaj0urnals.0rg/ by guest on November 13, 2014
`
`AM RNOO290182
`
`Hikma Pharmaceuticals
`
`IPR2022-00215
`
`Ex. 1008, p. 268 of 280
`
`

`

`3410
`
`860.
`
`861.
`
`862.
`
`863.
`
`864.
`
`865.
`
`866.
`
`867.
`
`868.
`
`869.
`
`870.
`
`5;i%e>e:t%s;*me>i' ?I$’:’,;M,
`
`Grundy SM, Vega GL, McGovern ME. Effects of
`extended-release niacin on lipoproteins and glycemic
`control in patients with type 2 diabetes mellitus: results
`of a randomized, double-blind, placebo-controlled mul-
`ticenter trial [Abstract]. JACC 2001;37(suppl A):249A.
`Elam MB, Hunninghake DB, Davis KB, Garg R,
`Johnson C, Egan D, Kostis JB, Sheps DS, Brinton EA,
`for the ADMlT lnvestigators. Effect of niacin on lipid
`and lipoprotein levels and glycemic control in patients
`with diabetes and peripheral arterial disease: the
`ADMlT study: a randomized trial. JAMA
`2000;284:1263-70.
`
`Etchason JA, Miller TD, Squires RW, Allison TG, Gau
`GT, Marttila JK, Kottke BA. Niacin-induced hepatitis:
`a potential side effect with low-dose time-release niacin.
`Mayo Clinic Proc 1991;66:23-8.
`
`Rader Jl, Calvert RJ, Hathcock JN. Hepatic toxicity
`of unmodified and time-release preparations of niacin.
`AmJMed1992;92:77-81.
`
`Mullin GE, Greenson JK, Mitchell MC. Fulminant
`hepatic failure after ingestion of sustained-release
`nicotinic acid. Ann Intern Med 1989; 1 1 1:253-5.
`
`Gibbons LW, Gonzalez V, Gordon N, Grundy S. The
`prevalence of side effects with regular and sustained-
`release nicotinic acid. Am JMed 1995;99:378-85.
`Pauciullo P, Marotta G, Rubba P, Cortese C, Caruso
`MG, Gnasso A, Fischetti A, Motti C, Mancini M. Serum
`lipoproteins, apolipoproteins and very low density
`lipoprotein subfractions during 6-month-fibrate treat-
`ment in primary hypertriglyceridaemia. J Intern Med
`1990;228:425-30.
`
`Leaf DA, Connor WE,
`lllingworth DR, Bacon SP,
`Sexton G. The hypolipidemic effects of gemfibrozil in
`type V hyperlipidemia: a double-blind, crossover study.
`JAMA 1989;262:3154-60.
`Gavish D, Oschry Y, Fainaru M, Eisenberg S. Change
`in very low-, low-, and high-density lipoproteins during
`lipid lowering (bezafibrate) therapy: studies in type HA
`and type llB hyperlipoproteinemia. Eur J Clin Invest
`1986;16:61-8.
`
`lllingworth DR, Olsen GD, Cook SF, Sexton GJ,
`Wendel HA, Connor WE. Ciprofibrate in the therapy
`of type ll hypercholesterolemia: a double-blind trial.
`Atherosclerosis 1982;44:211-21.
`
`Kornitzer M, Dramaix M, Vandenbroek MD, Everaert
`L, Gerlinger C. Efficacy and tolerance of 200 mg micro-
`nised fenofibrate administered over a 6-month period
`in hyperlipidaemic patients: an open Belgian multicenter
`study. Atherosclerosis 1994; 1 10 (suppl):S49-S54.
`
`871.
`
`872.
`
`873.
`
`874.
`
`875.
`
`876.
`
`877.
`
`878.
`
`879.
`
`880.
`
`881.
`
`882.
`
`Schoonjans K, Staels B, Auwerx J. Role of the peroxi-
`some proliferator-activated rece